NO964650L - LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff - Google Patents

LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff

Info

Publication number
NO964650L
NO964650L NO19964650A NO964650A NO964650L NO 964650 L NO964650 L NO 964650L NO 19964650 A NO19964650 A NO 19964650A NO 964650 A NO964650 A NO 964650A NO 964650 L NO964650 L NO 964650L
Authority
NO
Norway
Prior art keywords
preparation
lag
protein
soluble polypeptide
idiotype antibody
Prior art date
Application number
NO19964650A
Other languages
English (en)
Other versions
NO325828B1 (no
NO964650D0 (no
Inventor
Florence Faure
Thierry Hercend
Bertrand Huard
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Inst Nat Sante Rech Med
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Inst Nat Sante Rech Med, Applied Research Systems filed Critical Roussy Inst Gustave
Publication of NO964650D0 publication Critical patent/NO964650D0/no
Publication of NO964650L publication Critical patent/NO964650L/no
Publication of NO325828B1 publication Critical patent/NO325828B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19964650A 1994-05-06 1996-11-04 Anvendelse av et antistoff dannet mot et antigen. NO325828B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9405643 1994-05-06
PCT/FR1995/000593 WO1995030750A2 (fr) 1994-05-06 1995-05-05 Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype

Publications (3)

Publication Number Publication Date
NO964650D0 NO964650D0 (no) 1996-11-04
NO964650L true NO964650L (no) 1997-01-06
NO325828B1 NO325828B1 (no) 2008-07-28

Family

ID=9463004

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964650A NO325828B1 (no) 1994-05-06 1996-11-04 Anvendelse av et antistoff dannet mot et antigen.

Country Status (18)

Country Link
US (3) USRE38313E1 (no)
EP (1) EP0758383B1 (no)
JP (1) JP3700859B2 (no)
KR (1) KR100257466B1 (no)
CN (1) CN1110557C (no)
AT (1) ATE352617T1 (no)
BR (1) BR9507618A (no)
CA (1) CA2189657C (no)
DE (1) DE69535375T2 (no)
DK (1) DK0758383T3 (no)
ES (1) ES2281899T3 (no)
IL (1) IL113617A (no)
MX (1) MX9605365A (no)
NO (1) NO325828B1 (no)
PT (1) PT758383E (no)
RU (1) RU2178306C2 (no)
WO (1) WO1995030750A2 (no)
ZA (1) ZA953629B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0843557T3 (da) * 1995-07-21 2003-03-10 Inst Nat Sante Rech Med Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein
US6482925B1 (en) * 1996-11-28 2002-11-19 Applied Research Systems Ars Holding N.V. Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants
EP0941329B1 (en) 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
EP0900841A1 (en) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6434012B2 (en) * 2000-02-11 2002-08-13 Tyco Electronics Logistics Ag Circuit board interconnect
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US20040258678A1 (en) * 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
KR102454546B1 (ko) * 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
AU2017213633B2 (en) * 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
AU2017282892B2 (en) 2016-06-23 2023-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11390676B2 (en) 2016-10-13 2022-07-19 Symphogen A/S Anti-LAG-3 antibodies and compositions
EP3532046A4 (en) 2016-10-28 2020-12-30 Merck Sharp & Dohme Corp. A PURIFICATION PROCESS FOR REMOVING VARIANTS OF TYROSINE SULPHATION ANTIBODIES; PURIFIED COMPOSITIONS
TW201829462A (zh) 2016-11-02 2018-08-16 英商葛蘭素史克智慧財產（第二）有限公司 結合蛋白
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
KR102737715B1 (ko) 2017-04-05 2024-12-03 르 라보레또레 쎄르비에르 Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
WO2018208868A1 (en) * 2017-05-10 2018-11-15 Smet Pharmaceutical Inc Human monoclonal antibodies against lag3 and uses thereof
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
CA3073733A1 (en) 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anti-lag-3 antibodies and uses thereof
CA3085656A1 (en) * 2017-12-22 2019-06-27 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody pharmaceutical composition and use thereof
AU2020276242B2 (en) 2019-05-13 2025-01-30 Regeneron Pharmaceuticals, Inc. Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
CN115340606B (zh) * 2019-05-31 2023-12-19 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
EP4680342A1 (en) 2023-03-13 2026-01-21 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721983A1 (en) 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
CA2086325C (en) * 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
EP0758383B1 (fr) 2007-01-24
JP3700859B2 (ja) 2005-09-28
CN1155904A (zh) 1997-07-30
IL113617A (en) 2007-09-20
IL113617A0 (en) 1995-08-31
NO325828B1 (no) 2008-07-28
WO1995030750A3 (fr) 1995-12-21
DE69535375T2 (de) 2007-11-08
WO1995030750A2 (fr) 1995-11-16
CA2189657A1 (fr) 1995-11-16
RU2178306C2 (ru) 2002-01-20
ZA953629B (en) 1996-11-05
KR100257466B1 (ko) 2000-07-01
WO1995030750A8 (fr) 1999-07-29
US5955300A (en) 1999-09-21
BR9507618A (pt) 1997-08-19
CN1110557C (zh) 2003-06-04
ATE352617T1 (de) 2007-02-15
CA2189657C (fr) 2002-03-12
DK0758383T3 (da) 2007-05-29
NO964650D0 (no) 1996-11-04
AU708825B2 (en) 1999-08-12
JPH09508023A (ja) 1997-08-19
ES2281899T3 (es) 2007-10-01
EP0758383A1 (fr) 1997-02-19
MX9605365A (es) 1997-12-31
AU2570195A (en) 1995-11-29
US6143273A (en) 2000-11-07
KR970702917A (ko) 1997-06-10
DE69535375D1 (de) 2007-03-15
PT758383E (pt) 2007-05-31
USRE38313E1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
ATE430801T1 (de) Von wd-40 abstammende peptide und ihre verwendung
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
DE69738432D1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
IL134982A0 (en) Antibodies which react with polypeptides of cd-44 surface proteins and diagnostic and pharmaceutical compositions prepared therewith
ATE301714T1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
DE69715181D1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
EP0992584A3 (en) Purified mammalian FLT3 ligands and agonists and antagonists thereof
DE69607034D1 (de) Pcna bindende substanz
EP1132402A4 (en) PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
ATE161543T1 (de) Aminoterminale prokollagen 1(i) peptide
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
DE59813388D1 (de) Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 von Cytomegalovirus und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired